{
    "case_number": "CAC-UDRP-107424",
    "time_of_filling": "2025-03-24 08:45:06",
    "domain_names": [
        "novartis-pharma-france.com"
    ],
    "case_administrator": "  Iveta Špiclová   (Czech Arbitration Court) (Case admin)",
    "complainant": [
        "Novartis AG"
    ],
    "complainant_representative": "Abion GmbH",
    "respondent": [
        "Wahab SALISA"
    ],
    "respondent_representative": null,
    "factual_background": "<p>The Complainant was established in 1996 through a merger of Ciba-Geigy and Sandoz, and is one of the biggest global pharmaceutical and healthcare groups which develops and distributes medical treatments and drugs. In 2024, the Complainant achieved net sales of USD 50.3 billion, its total net income amounted to USD 11.9 billion and it employed approximately 76,000 full-time equivalent employees. The Complainant&rsquo;s products are manufactured and sold in many countries worldwide, including in France, where it has an active presence through associated companies and subsidiaries.<\/p>\n<p>The disputed domain name was registered on January 26, 2025 and, after briefly resolving to a parking site, is currently inactive. The disputed domain name was configured with MX (mail exchange) records.<span><\/span><\/p>\n<p><span><\/span><\/p>",
    "other_legal_proceedings": "<p>The Panel is not aware of any other legal proceedings which are pending or decided and which relate to the disputed domain name.<\/p>",
    "no_response_filed": "<p>The Complainant contends that the requirements of the Policy have been met and that the disputed domain name should be transferred to it.<\/p>\n<p>No administratively compliant Response has been filed.<\/p>",
    "rights": "<p>The Complainant has, to the satisfaction of the Panel, shown the disputed domain name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the Policy).<\/p>",
    "no_rights_or_legitimate_interests": "<p>The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the disputed domain name (within the meaning of paragraph 4(a)(ii) of the Policy).<\/p>",
    "bad_faith": "<p>The Complainant has, to the satisfaction of the Panel, shown the disputed domain name has been registered and is being used in bad faith (within the meaning of paragraph 4(a)(iii) of the Policy).<\/p>",
    "procedural_factors": "<p>The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision.<\/p>",
    "decision": "Accepted",
    "panelists": [
        "Alfred Meijboom"
    ],
    "date_of_panel_decision": "2025-04-18 00:00:00",
    "informal_english_translation": "<p><span>The Complainant is owner of <em>inter alia<\/em>:<\/span><\/p>\n<ul>\n<li><span>International trademark NOVARTIS, with registration number 1349878, of November 29, 2016, for goods and services in classes 1, 3, 5, 9, 10, 16, 29, 30, 31, 32, 35, 40,&nbsp;41, 42 and 44, which designate several jurisdictions, including the African Intellectual Property Organization, of which Togo is a member state;<\/span><\/li>\n<li><span>International trademark NOVARTIS, with registration number 1249666, of April 28, 2015, for goods and services in classes 9, 10, 41, 42, 44 and 45, designating the African Intellectual Property Organization; and<\/span><\/li>\n<li><span>European Union trademark NOVARTIS with registration number 304857 of June 25, 1999 for goods in classes1, 5, 9, 10, 29, 30, 31 and 32.<\/span><\/li>\n<\/ul>",
    "decision_domains": {
        "novartis-pharma-france.com": "TRANSFERRED"
    },
    "panelist": null,
    "panellists_text": null
}